Key Insights

Highlights

Success Rate

84% trial completion

Published Results

11 trials with published results (18%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.8%

6 terminated out of 61 trials

Success Rate

83.8%

-2.7% vs benchmark

Late-Stage Pipeline

8%

5 trials in Phase 3/4

Results Transparency

35%

11 of 31 completed with results

Key Signals

11 with results84% success

Data Visualizations

Phase Distribution

39Total
Not Applicable (11)
Early P 1 (1)
P 1 (9)
P 2 (13)
P 3 (3)
P 4 (2)

Trial Status

Completed31
Unknown12
Terminated6
Recruiting6
Withdrawn2
Active Not Recruiting2

Trial Success Rate

83.8%

Benchmark: 86.5%

Based on 31 completed trials

Clinical Trials (61)

Showing 20 of 20 trials
NCT07222800Phase 3Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT05294107Not ApplicableActive Not RecruitingPrimary

Intestinal Organoids

NCT07351071Not ApplicableRecruiting

Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections

NCT07366151Not Yet Recruiting

Long-term Health Outcomes of Screen Detected and Potential Celiac Disease Patients

NCT06653647Not ApplicableCompleted

Efficacy of Guided Imagery Therapy Mobile Application for Functional Abdominal Pain

NCT02613403Phase 2Terminated

Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)

NCT02831556Completed

Point of Care 3D Ultrasound for Various Applications: A Pilot Study

NCT01832116Phase 1Completed

89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients

NCT02647866Phase 2Completed

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

NCT06365866Not ApplicableRecruiting

Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.

NCT05494060Phase 2Recruiting

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

NCT05602935Phase 2Active Not Recruiting

Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study

NCT04644315Phase 2Terminated

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

NCT01964430Phase 3Completed

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)

NCT03717298Phase 2Completed

Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

NCT04949282Recruiting

Spanish Series of Patients Treated With the Radionuclide Lutetium177

NCT05252078Phase 2Recruiting

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

NCT04977739Completed

Research on the Application and Mechanism of New Biological Probes in Biomedicine

NCT04080843Phase 2Completed

Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients

NCT04639115Phase 1Completed

A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod

Scroll to load more

Research Network

Activity Timeline